- Policy
- GC Pharma is working on developing DM combination drugs
- by Lee, Tak-Sun Jun 15, 2021 05:52am
- GC Pharma is busy building a lineup of ARB-based hypertension drugs called Candesartan. If Atacand, which is Candesartan's original product, has been sold for a long time, it can be seen as a measure to actively utilize its distribution network. It is currently pushing for development of other complexes in addition to single and two complexes
- Policy
- Hepatitis C Txs are rapidly being replaced with new drugs
- by Lee, Tak-Sun Jun 14, 2021 05:56am
- Chronic hepatitis C treatments are being withdrawn from the market as new drugs are released. Roche's Pegasys, a treatment for hepatitis B and C infection, eventually withdrew from the Korean market. Pegasys PFS products were revoked on the 8th. Pegasys, which was approved in Korea in 2004, was expected to be a hepatitis C treatment in
- Policy
- 1 in 5 people received COVID-19 vaccinations in Korea
- by Kim, Jung-Ju Jun 11, 2021 05:53am
- With the number of daily COVID-19 cases constantly in the 500 range, over 10 million people in Korea have received one or more shots of COVID-19 vaccines. This is nearly 20% of the total population, in other words, 1 out of 5 people in Korea have now been vaccinated. In the midst of the increasing outdoor activities and the upcoming summe
- Policy
- Moderna vaccine, 100% effective for Asians in clinical trial
- by Lee, Tak-Sun Jun 11, 2021 05:53am
- Moderna's COVID-19 vaccine has been shown to be 100% effective in Asian clinical trials. However, there is a limit to reaching a meaningful conclusion because there are fewer test subjects. The minutes of the Central Pharmaceutical Affairs Review Committee, released by the MFDS on the 7th, contain this information. The Central Pharmaceutic
- Policy
- OTC combination drug with APAP-IBU, not approved again
- by Lee, Tak-Sun Jun 11, 2021 05:53am
- OTC approval of APAP-IBU complex has failed again. Experts who participated in the review objected to the permission on the grounds that safety issues had not been resolved. According to the Central Pharmaceutical Affairs Review Committee minutes released on the 7th, seven out of 10 members opposed the OTC approval of Acetaminophen-Ibuprof
- Policy
- 5 companies' developing vaccines have completed Phase I
- by Kim, Jung-Ju Jun 10, 2021 05:55am
- The development products of five companies that are developing domestic COVID-19 vaccines have all been found to have completed phase 1 clinical trial and entered the next stage Depending on the product, some vaccines are aimed at entering phase 3 clinical trials as early as next month (July). The MOHW reported the status of vaccine develo
- Policy
- 200 million tablets of Acetaminophen are available
- by Kim, Jung-Ju Jun 9, 2021 06:07am
- The government has stressed that Acetaminophen is well stocked before more people are vaccinated. Pre-dosing before inoculation does not fit medical information and does not require purchasing only certain brands (ex:Tylenol). COVID-19 Central Disaster and Safety Counters Headquaters (CDSCHQ) told in a regular briefing this afternoon that
- Policy
- PVA is a variable in the negotiation of α-GPC recovery
- by Lee, Hye-Kyung Jun 8, 2021 06:01am
- Re-negotiation on benefit recovery and PVA negotiation related to pharmaceuticals with the brain functional improvement agent "Choline alfoscerate" have emerged as variables. On the 3rd, the MOHW ordered the NHIS to conduct negotiations on 123 items of Choline alfoscerate for 40 days from June 4 to July 13. Choline alfoscerate recovery
- Policy
- Pipeltro/Delstrigo will be reimbursed if the amount offered
- by Lee, Hye-Kyung Jun 8, 2021 06:00am
- Pipeltro (Doravirine) and Delstrigo (Doravirine, Lamivudine, Tenofovir), the HIV treatment by MSD, are the two major human immunodeficiency virus. And, were declared "Conditional Coverage" at the first step of the reimbursement if it was accepted below the appraised amount. On the 3rd, the HIRA held the 5th Pharmaceutical Benefits Advisory Co
- Policy
- Ultomiris can be reimbursed with prior approval
- by Lee, Hye-Kyung Jun 7, 2021 06:06am
- Ultomiris (Ravulizumab), Handok's paroxysmal nocturnal hemoglobinuria (PNH) treatment, will be listed at &8361;5,598,942 per bottle starting today (7th). The upper limit price for Soliris (30ml) is &8361;5,132,364, so if 3 vials are administered every other week, about &8361;400 million won is needed for a year. Ultomiris, on the ot
